Connecting Men, Families, Doctors, and other Medical Professionals to Clinical Trials for Prostate Cancer

        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed adenocarcinoma of the prostate

               -  Metastatic disease as evidenced by soft tissue and/or bony metastases, including
                  >= 1 of the following:

                    -  Visceral disease (liver, lung, or other viscera)

                    -  Bone metastases to sites in either the axial (spine, pelvis, ribs, or
                       skull) and/or the appendicular (clavicle, humerus, or femur) skeleton

                    -  Lymph node disease not considered to be encompassed within a single
                       radiotherapy port (e.g., above the aortic bifurcation)

          -  Patients with measurable disease must have radiographic assessment (at least an
             abdominal/pelvic CT scan) within the past 28 days

               -  Patients with non-measurable disease must be assessed (e.g., bone scan) within
                  the past 42 days

          -  PSA >= 5 ng/mL within 90 days before initiation of androgen-deprivation therapy

          -  No known brain metastases

               -  Brain imaging studies not required for patients with no neurologic signs or
                  symptoms

        PATIENT CHARACTERISTICS:

          -  Zubrod performance status (PS) 0-2

               -  Zubrod PS 3 allowed if due to bone pain

          -  WBC >= 3,000/mm^3

          -  ANC >= 1,500/mm^3

          -  Platelet count >= 100,000/mm^3

          -  Hemoglobin >= 9 g/dL

          -  Bilirubin <= 1.5 times upper limit of normal (ULN)

          -  AST and ALT <= 3 times ULN (<= 5 times ULN for liver metastases)

          -  Creatinine <= 2.0 times ULN OR creatinine clearance >= 40 mL/min

          -  INR <= 1.5

          -  PTT <= 5 seconds above the ULN

          -  HgA1C <= 7 AND fasting glucose < 160 mg/dL or below ULN

               -  Patients with diabetes mellitus who meet this criterion are eligible provided
                  they are on a stable dietary or therapeutic regimen

          -  Fertile patients must use effective contraception during and for >= 3 months after
             completion of study therapy

          -  No known LVEF >= 10% below the lower limit of normal

               -  Patients with suspected LV dysfunction not confirmed by review of medical
                  history must undergo MUGA or ECHO within 90 days before study entry

          -  No history of symptomatic congestive heart failure

          -  No history of allergic reaction attributed to compounds of similar chemical or
             biological composition to cixutumumab

          -  No other malignancy within the past 5 years except adequately treated basal cell or
             squamous cell skin cancer or stage I or II cancer currently in complete remission

        PRIOR CONCURRENT THERAPY:

          -  Prior medical castration allowed provided it was initiated within the past 30 days

               -  Patients on a luteinizing hormone-releasing hormone (LHRH) agonist (e.g.,
                  leuprolide acetate or goserelin) must be willing to continue the LHRH agonist in
                  addition to bicalutamide during study treatment

               -  Patients on a different anti-androgen (e.g., flutamide) must be willing change
                  to bicalutamide during study treatment

          -  Prior bilateral orchiectomy allowed provided it was performed within the past 30 days

          -  At least 28 days since prior non-orchiectomy surgery and recovered

          -  More than 28 days since prior strontium-89, rhenium-186, rhenium-188, or samarium-153
             radionuclide therapy

          -  At least 28 days since prior radiotherapy or biologic therapy (e.g., vaccines,
             immunotherapy, anti-sense agents, small molecules, or monoclonal antibodies) and
             recovered

          -  No prior cytotoxic chemotherapy for metastatic prostate cancer

          -  No prior treatment with agents that directly inhibit IGF or IGFR

          -  No prior chimerized or murine monoclonal antibody therapy

          -  No concurrent antiretroviral therapy for HIV-positive patients

          -  No concurrent treatment with any of the following:

               -  Chemotherapy

               -  Hormonal therapy (other than the LHRH agonist and oral anti-androgen)

               -  Radiotherapy

               -  Immunotherapy

               -  Any other anticancer therapy

               -  5-alpha reductase inhibitors (e.g., finasteride or dutasteride)

               -  Ketoconazole

               -  Diethylstilbestrol/DES

               -  Other estrogen-based therapy

          -  Concurrent prophylactic low-dose coumadin or low-molecular weight heparin allowed
             provided coagulation criteria are met

               -  Patients requiring full-dose (therapeutic) anticoagulation are eligible provided
                  they are on a stable dose of anticoagulation AND the coagulation parameters are
                  stable within the therapeutic range (e.g., INR 2-3 for patients on therapeutic
                  warfarin)